Insilico Medicine
Founded: 2014
Location: Hong Kong/New York
CEO: Alex Zhavoronkov, Ph.D.
Total Funding: $424.3M (as of 2023)
Latest Valuation: >$1B (Unicorn status)
14
Drug Candidates
30+
Partnerships
200+
Peer-reviewed Publications
Technology Platform
PharmaAI
End-to-end AI platform for drug discovery and development:
- Chemistry42: De novo small molecule generation and optimization
- PandaOmics: AI-driven target discovery
- InClinico: Clinical trial outcome prediction
Pipeline Highlights
ISM001-055: Fibrosis treatment
Status: Phase I Clinical Trials
ISM003-268: Cancer treatment
Status: IND-enabling studies
Key Partnerships
- Sanofi: $1.2B deal for AI-driven drug development (2022)
- Teva Pharmaceuticals: Strategic collaboration for AI drug discovery
- Fosun Pharma: Joint development agreement for China market
Competitive Advantages
- End-to-end AI platform covering entire drug development process
- Proven track record of rapid drug candidate discovery (weeks vs years)
- Strong IP portfolio with multiple patents
- Demonstrated success in bringing AI-discovered drugs to clinical trials
Atomwise
Founded: 2012
Location: San Francisco, CA
CEO: Abraham Heifets
Total Funding: $174M
Latest Round: Series B (2020)
1000+
Projects
500+
Research Collaborations
17B+
Compounds Analyzed
Technology Platform
AtomNet Platform
Deep learning platform for small molecule drug discovery:
- Structure-based drug design
- Molecular property prediction
- Hit discovery and optimization
- Multi-parameter optimization
Key Differentiators
- First to apply deep learning to drug discovery (2012)
- Proprietary 3D deep learning architecture
- Demonstrated success in finding novel binding sites
- Proven ability to identify active compounds across diverse targets
Notable Partnerships
- Eli Lilly: Multi-target drug discovery collaboration
- Hansoh Pharma: Strategic partnership for novel drug development
- Bridge Biotherapeutics: Collaboration for drug discovery
DeepMind (Isomorphic Labs)
Founded: 2021 (Isomorphic Labs)
Location: London, UK
CEO: Demis Hassabis
Parent Company: Alphabet (Google)
Resources: Backed by Google's infrastructure
200M+
Protein Structures
92.4%
Prediction Accuracy
$1B+
Research Investment
Core Technologies
AlphaFold
Revolutionary protein structure prediction system:
- Accurate 3D protein structure prediction
- Protein-protein interaction modeling
- Structure-based drug design capabilities
Advanced AI Systems
- Novel molecular design algorithms
- Multi-scale biological modeling
- Integration with experimental data
Strategic Advantages
- Access to Google's computational resources and expertise
- Built on DeepMind's proven AI capabilities
- Integration with AlphaFold's breakthrough technology
- Strong academic and research partnerships
BenevolentAI
Founded: 2013
Location: London, UK
CEO: Joanna Shields
Market Cap: Listed on Euronext Amsterdam
Total Funding: >$292M (pre-IPO)
30+
Drug Programs
20+
Disease Areas
250+
Scientists & Engineers
Technology Platform
Benevolent Platform
Integrated AI and machine learning platform:
- Knowledge Graph with billions of data points
- Target identification and validation
- Molecular design and optimization
- Patient stratification
Pipeline & Achievements
BEN-2293: Atopic dermatitis
Status: Phase I/II Clinical Trials
AstraZeneca Collaboration: CKD & IPF
Status: Multiple programs in development
Market Differentiation
- Public company with transparent operations
- Proven success in COVID-19 drug repurposing
- Strong focus on rare and complex diseases
- Extensive validation through pharma partnerships